Disclosure of Interests
Allan Kember is the majority shareholder and the volunteer (unpaid)
Chief Executive Officer and President of a startup company, Shiphrah
Biomedical Inc. (SBI), which was one of the study funders. Allan Kember
received financial payment from Mitacs through an entrepreneurship
internship as part of his graduate studies at the University of Toronto
(UofT). Min-En Hsieh received financial payment from Mitacs and UofT to
complete an international exchange internship with SBI as part of his
graduate studies at National Cheng Kung University. The other authors
report no conflict of interest.